Serum Kisspeptin-10 Levels in Pregnant Women Complicated with Intrauterine Growth Restriction With or Without Preeclampsia

Khalil, Sama S.; Abulfadle, Khaled Abdelfattah; Elnagar, Walid Mohamed

doi:10.21608/mjcu.2018.56929

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…KP levels are consistently reduced in IUGR ( 113 , 114 ) and pregnancies with SGA ( 107 , 112 ) and therefore KP could aid in the assessment of these conditions (see Table 1L ). In contrast, in preterm birth (delivery prior to 37 weeks’ gestation ( 216 )), circulating KP levels were increased during the first trimester but were unaltered in the third trimester ( 107 ).…”

Section: Clinical Applications Of Kisspeptinmentioning

confidence: 99%

The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B

et al. 2023

View full text Add to dashboard Cite

Kisspeptin (KP) and neurokinin B (NKB) are neuropeptides that govern the reproductive endocrine axis through regulating hypothalamic gonadotropin-releasing hormone (GnRH) neuronal activity and pulsatile GnRH secretion. Their critical role in reproductive health was first identified after inactivating variants in genes encoding for KP or NKB signaling were shown to result in congenital hypogonadotropic hypogonadism (CHH) and a failure of pubertal development. Over the past two decades since their discovery, a wealth of evidence from both basic and translational research has laid the foundation for potential therapeutic applications. Beyond KP’s function in the hypothalamus, it is also expressed in the placenta, liver, pancreas, adipose tissue, bone, and limbic regions, giving rise to several avenues of research for use in the diagnosis and treatment of pregnancy, metabolic, liver, bone, and behavioral disorders. The role played by NKB in stimulating the hypothalamic thermoregulatory center to mediate menopausal hot flashes has led to the development of medications that antagonize its action as a novel non-steroidal therapeutic agent for this indication. Furthermore, the ability of NKB antagonism to partially suppress (but not abolish) the reproductive endocrine axis has supported its potential use for the treatment of various reproductive disorders including polycystic ovary syndrome (PCOS), uterine fibroids, and endometriosis. This review will provide a comprehensive up-to-date overview of the preclinical and clinical data that have paved the way for the development of diagnostic and therapeutic applications of KP and NKB.

show abstract

Section: Clinical Applications Of Kisspeptinmentioning

confidence: 99%

The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B

et al. 2023

View full text Add to dashboard Cite

show abstract

Kisspeptins and Glucose Homeostasis in Pregnancy: Implications for Gestational Diabetes Mellitus—a Review Article

2021

View full text Add to dashboard Cite

Kisspeptin-10: A Predictor for Fetal Growth Restriction among Preeclamptic Women that Discriminated Early Onset Cases

Abdalqader,

Hussein,

Jadi

et al. 2024

Clin. Exp. Obstet. Gynecol.

View full text Add to dashboard Cite

Background: Preeclampsia (PE) is a major cause of maternal and neonatal morbidity. Fetal growth restriction (FGR) shares many pathophysiological roles with PE. Kisspeptin-10 is a peptide secreted by placental syncytium. It was linked to many adverse pregnancy events. The current study aimed to examine Kisspeptin’s-10 role in predicting FGR in PE pregnancies and to verify whether it can predict its onset as early or late FGR. Methods: An observational case-control study enrolled 120 eligible cases at matched gestational age (28–40 weeks) and body mass index (BMI); they were divided into 2-groups: (60) healthy controls and (60) PE cases. PE cases were subdivided into early onset FGR (28/60), who had a gestational age less than 34 weeks, and late-onset FGR (32/60) with a gestational age equal to 34 weeks. A collection was made of the following data: first: pregnant primary criteria [age, BMI, systolic and diastolic blood pressure (BP), and urine for albumin], second: serum Kisspetein-10 was evaluated via enzyme-linked immunosorbent assay (ELISA), and third: ultrasonic criteria [estimated fetal weight, resistance, and pulsatility index (RI, PI)] were recorded for all. Results: Serum Kisspeptin-10 was significantly higher among the controls (309.56 ± 67.72) followed by late-onset FGR and early onset FGR (235.46 ± 68.97) vs. (212.09 ± 58.44) ng/dL; p = 0.0001 respectively. It was negatively linked to systolic, diastolic BP, and urine for albumin; Pearson correlation coefficient (r) was (–0.29, –0.48, –0.28) respectively; p < 0.0001, 0.0018, 0.028 respectively. Kisspeptin-10 was positively linked to estimated fetal weight (r = 0.27; p = 0.034); it had an odds ratio (OR) of 3.04; 95% confidence interval of (1.37–4.765); p = 0.0001 in discriminating healthy pregnancies from FGR cases. Conclusions: The significant correlation of Kisspeptin-10 with PE parameters and estimated fetal weight with high sensitivity, specificity and reliable area under the curve in predicting early onset FGR cases make it recommended for practice in predicting FGR onset.

show abstract

Serum Kisspeptin-10 Levels in Pregnant Women Complicated with Intrauterine Growth Restriction With or Without Preeclampsia

Cited by 4 publications

References 0 publications

The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B

The Emerging Therapeutic Potential of Kisspeptin and Neurokinin B

Kisspeptins and Glucose Homeostasis in Pregnancy: Implications for Gestational Diabetes Mellitus—a Review Article

Kisspeptin-10: A Predictor for Fetal Growth Restriction among Preeclamptic Women that Discriminated Early Onset Cases

Contact Info

Product

Resources

About